Premium
Immunosuppression considerations in simultaneous organ transplant
Author(s) -
Kovac Danielle,
Choe Jason,
Liu Esther,
Scheffert Jenna,
Hedvat Jessica,
Anamisis Anastasia,
Salerno David,
Lange Nicholas,
Jennings Douglas L.
Publication year - 2021
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/phar.2495
Subject(s) - immunosuppression , medicine , organ transplantation , kidney , intensive care medicine , lung , solid organ , kidney transplantation , transplantation , immunology , surgery
Solid organ transplantation is a life‐saving procedure for patients in the end stage of heart, lung, kidney, and liver failure. For patients with more than one failing organ, simultaneous organ transplantation has emerged as a viable treatment option. Immunosuppression strategies and outcomes for simultaneous organ transplant recipients have been reported, but often involve limited populations. Transplanting dual organs poses challenges in terms of balancing immunosuppression with immunologic risk and allograft damage from surgical complications. Furthermore, transplanting certain organs can impose considerations on the management of immunosuppression. For example, liver allografts may confer immunologic privilege and lower rates of rejection of other allografts. This review article evaluates immunosuppression strategies for simultaneous kidney‐pancreas, liver‐kidney, heart‐kidney, heart‐liver, heart‐lung, lung‐liver, and lung‐kidney transplants. To date, no comprehensive review exists to address immunosuppressive strategies in simultaneous organ transplant populations. Our review summarizes the available literature and provides evidence‐based recommendations regarding immunosuppression strategies in simultaneous organ transplant recipients.